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background: Although statin therapy is beneficial for vascular diseases, the relationship between specific statin therapy and incidence of new-
onset diabetes mellitus(DM) remains uncertain. We evaluated the impact of Simvastatin therapy on the development of new-onset DM from 3-year 
clinical follow up data in a series of Asian population.
methods: A total of 3,436 consecutive patients who did not have DM were enrolled. New-onset DM was defined as having a fasting blood glucose 
≥126mg/dL or HbA1c ≥6.5%. Baseline characteristics between the Simvastatin and the control group were propensity score matched (PSM, 
C-statics=0.808).
results: At baseline, patients in the Simvastatin group showed higher prevalence of elderly, male gender,dyslipidemia, coronary artery disease, 
smoking and alcoholic history, and higher levels of HbA1c, fasting glucose, triglyceride, fibrinogen, and ALP. 3-year clinical follow up results showed 
a higher incidence of new-onset DM in the Simvastatin group (3.8% vs. 2%, p=0.017). Following PSM (C-statics=0.808), the 2 groups were well 
balanced except for higher levels of fibrinogen, ALT, and ALP in the Simvastatin group. After adjustment, there was no difference in the incidence of 
new-onset DM between the 2 groups up to 3 years (Figure).
conclusions: In our study, the relationship between the use of Simvastatin and the incidence of new-onset DM remains unclear. Long-term follow 
up with a larger study population will be necessary for further information.
 
